Conférences
le (14m46s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 94
Label UNT Conférences
le (15m24s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Standard of care and novel opportunities for CV prevention and the treatment of heart failure in patients with moderate to severe CKD?
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Standard of care and novel opportunities for CV prevention and the treatment of heart failure in patients with moderate to severe CKD?Speaker: Hermann HALLER, Hannover, GERAbstract : Patients with chronic kidney disease are both at risk developing chronic vascular disease as well as progression of the renal disease. These risks are especially important for patients with metabolic disease such as diabetes and hypercholesterolemia. Several approaches have been used to prevent cardiovascular disease in these patients: The contribution of existing antihypertensive therapy to prevent the mechanisms of inflammation, oxidative stress and fibrosis ... Voir la vidéo
Label UNT Conférences
le (4m38s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpointsSpeaker: John JARCHO, Boston, USA, NEJMDiscussant: Rita REDBERG, San Francisco, USA, Arch Intern MedAbstract : Biomarker studies have proliferated widely, but the actual impact of most such studies on the practice of medicine is modest. One major underlying problem is a lack of clarity (on the part of both investigators and readers) about what biomarker data can be expected to contribute. In many cases, studies merely demonstrate a statistical association between a putative biomarker and a clinical correlate, but the implications of this association are not made explicit. In ... Voir la vidéo
Label UNT Conférences
le (11m39s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developmentsSpeaker: Hermann HALLER, Hannover, GERDiscussant: Yared NADIM, CVRx, USAAbstract : Barostim: Experience so far and future developmentsL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 HYPERTENSION TRIALIST WORKSHOP: AUTONOMIC MODULATION THERAPYChairpersons: George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORResistant hypertension is usually defined as uncontrolled hypertension despite the intake of at least 3 antihypertensive drugs in full doses including a diuretic. Most investigators would ... Voir la vidéo
Label UNT Conférences
le (5m4s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementL’auteur n’a pas transmis de conflit ... Voir la vidéo
Conférences
le (22m57s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for securing approval and reimbursement (Andrew FARB - Ileana PIÑA)
MODIGLIANI Debate Session 4 - SATURday DECember 1st, 2012:HEART FAILURE REMOTE MONITORING TRIALSChairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USAWebcast: Daniela DOBRE, Nancy, FRACase studies and ultimate methodology for future trialsRemote monitoring remains an appealing option for following patients after a heart-failure hospitalization. Trials employing common strategies (simple phone calls with a nurse and Telemonitoring of vital signs) have in general not demonstrated improvement in survival and or reduction in risk of readmission; meta-analysis of telemonitoring trials using these common strategies, however, have shown improvements in survival and hospitalization rates. Recently, trials of more complex implanted remote ... Voir la vidéo
Conférences
le (1h17m57s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issues: Pathway to a more global device approval process (Ileana PIÑA)
MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012THE DEVICE THERAPY TRIALISTS WORKSHOPChairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USAWebcast: Tariq AHMAD, Durham, USADevice trial methodology, regulatory and implementation issuesAdvances in interventional medical devices are increasingly affecting cardiovascular therapy, just as pharmacological innovation did the generation before. Yet, designing and conducting a device trial is challenging and drug trial designs may not necessarily be applied fully to device trials.➢ Although there is increasing recognition that this development process substantially differs from that for drugs, how much device trial methodology may deviate from drug trial methodology ... Voir la vidéo
Conférences
le (10m8s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Ileana PIÑA)
MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012THE DEVICE THERAPY TRIALISTS WORKSHOPChairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USAWebcast: Tariq AHMAD, Durham, USADevice trial methodology, regulatory and implementation issuesAdvances in interventional medical devices are increasingly affecting cardiovascular therapy, just as pharmacological innovation did the generation before. Yet, designing and conducting a device trial is challenging and drug trial designs may not necessarily be applied fully to device trials.➢ Although there is increasing recognition that this development process substantially differs from that for drugs, how much device trial methodology may deviate from drug trial methodology ... Voir la vidéo
Label UNT Conférences
le (12m17s)
IP3S Lille 2012 : IDEFI – SAMSEI Stratégies d’Apprentissage des Métiers de Santé en Environnement Immersif.
Titre : IP3S Lille 2012 : IDEFI – SAMSEI Stratégies d’Apprentissage des Métiers de Santé en Environnement Immersif.Auteurs : Xavier MARTIN, Lyon 1Résumé : Le projet SAMSEI (Stratégies d’Apprentissage des Métiers de Santé en Environnement Immersif) a pour objectif la mise en place d’un programme pédagogique basé sur la simulation pour un apprentissage participa- tif et immersif destiné aux étudiants de toutes les filières de santé de l’Université Lyon1 et de ses partenaires.Ce programme pédagogique repose sur quatre axes :- l’introduction et la pérennisation de la méthode pédagogique de simulation en formation initiale et continue, en particulier pour les disciplines exposées aux urgences et ... Voir la vidéo
Label UNT Conférences
le (11m20s)
